Overview

            Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases including neuropathic pain, multiple sclerosis and ALS. Xalud's lead product, XT-101, has shown exceptional efficacy in leading models of both neuropathic and chronic pain as well in the EAE model of multiple sclerosis.

        Xalud (pronounced as "Salud", to your health!) is currently conducting IND-enabling toxicology and related studies and expects to file an IND in the first half of 2014 for a neuropathic pain indication. At the same time, the Company is continuing its research into the applicability of XT-101 for MS and ALS.

         Based in the Boulder, Colorado and San Francisco, California, Xalud has received over $3 Million in grant funding from the NIH and philanthropic disease foundations.